The Blackstone Group has made its first transaction in Japan, agreeing to acquire Ayumi Pharmaceutical Corporation from Unison Capital and medical information site operator M3.
Everlife, an Asia healthcare investment platform managed by India’s Everstone Group, has made its first investment in India, committing an undisclosed amount to medical device manufacturer CPC Diagnostics.
Singapore-based digital health start-up CXA Group has raised $25 million in funding from a string of strategic backers, including HSBC and the Asia investment arms of Singtel and Sumitomo Corporation.
Advantech Capital and CMB International, an investment unit of China Merchants Bank, have led a $70 million Series C funding round for InventisBio, a Chinese clinical stage biotech company.
Singapore-based United Overseas Bank (UOB) has led a $65 million Series B round for Indonesian healthcare technology provider Halodoc.
True North has acquired a 51% stake in Max Bupa Health Insurance, a joint venture between multinational insurance giant Bupa Group and Indian conglomerate Max India, for INR5.1 billion ($72 million).
Japan Hospice Holdings, a hospice care platform created by J-Star through a series of acquisitions, is looking to raise JPY1.48 billion ($13.4 million) through a Tokyo IPO.
Chinese gym operator SuperMonkey has raised RMB360 million ($53.5 million) in a Series D round led by Starquest Capital and Yao Capital, a sport-focused PE firm co-founded by former NBA star Yao Ming.
TPG Capital Asia’s Pathology Asia platform has continued a regional roll-up strategy with an investment of undisclosed size in a minority stake in Australian drug testing specialist Safe Work Laboratories.
Jinxin Fertility, the assisted reproduction services division of China’s Jinxin Group that is backed by several private equity investors, has filed for an IPO in Hong Kong.
Lilly Asia Ventures (LAV) has closed its fifth healthcare fund – which operates globally but primarily backs companies with a China angle – at the hard cap of $750 million. It represents a meaningful step up in size from the $450 million raised for...
Shukun, a Chinese company that provides artificial intelligence (AI) technology used in the treatment of cardiovascular diseases, has raised RMB200 million ($29 million) in a Series B round led by China Creation Ventures.
Having raised $250 million for its third India healthcare fund, Invascent Capital plans to take advantage of a greater willingness among entrepreneurs to work with financial investors
GIC Private has led a RMB850 million ($125.5 million) Series C round for Burning Rock, a Chinese cancer diagnostics start-up that is already working with hospitals on products based on DNA sequencing analysis.
Sciwind Biosciences, a Chinese drug developer focused on treating metabolic disorders, has raised RMB200 million ($29 million) in Series A funding led by Legend Capital, with participation from existing investors Shiyu Capital and Beijing-based biotech...
New Zealand’s Direct Capital has acquired a minority stake in local retirement village operator Qestral Corporation for an undisclosed sum.
Singapore’s Temasek Holdings has invested INR 2.7 billion ($38.1 million) in India's Dr. Agarwal’s Healthcare to support the expansion of its publicly listed eyecare chain Dr. Agarwal’s Eye Hospital.
Vision Knight Capital has led a RMB200 million ($29 million) Series C round for Soocas, a Shenzhen-based manufacturer of personal care products such as electric toothbrushes and hairdryers.
C-Bridge Capital has announced a licensing agreement with Samsung Bioepis that is intended to help the Korean biopharmaceutical specialist expand into the China market.
Shanghai-based cancer drug developer HaiHe Biopharma has raised $146.6 million in a funding round led by Chinese private equity firm Huagai Capital.
J-Will Partners has won board support for its proposed acquisition of ND Sofware, a Japanese software developer that serves the healthcare sector, through a tender offer at a valuation of JPY29.9 billion ($272 million).
IDG Capital and Lilly Asia Ventures (LAV) have joined a $10 million investment in EdiGene, a developer of genetics-based therapies based in Beijing.
TPG Growth, the mid-market investment platform of TPG Capital, has invested $30 million in Indian pharmaceutical ingredient maker Solara Active Pharma.
Australia-listed hospital operator Healthscope has agreed to a take-private offer by Brookfield Asset Management that values the company at A$4.38 billion ($3.17 billion) on an equity basis, rejecting a competing offer from a consortium led by BGH Capital.